Global Antibody Drug Conjugates (ADC) Market Research Report 2022 –

DUBLIN–(BUSINESS WIRE)–The “Antibody Drug Conjugates Market Size, Share & Trends Analysis Report by Application (Blood Cancer, Breast Cancer, Urothelial/Bladder Cancer), by Technology (Cleavable, Non-cleavable Linker, Linkerless), and Segment Forecasts, 2022-2030” report has been added to’s offering.

The global antibody drug conjugates market size is expected to reach over USD 22.87 billion by 2030, registering a CAGR of 16.4%

The presence of strong pipeline products and strategic initiatives undertaken by the key players are expected to drive the market growth during the forecast period.

Key players such as ADC Therapeutics, Seagen. Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca, Daiichi Sankyo, and others are collaborating to develop and commercialize products.

For instance, in February 2022, Mersana Therapeutics, partnered with Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson Inc., for the research and development of novel ADCs to treat various cancers. Under this agreement, Janssen will pay Mersana Therapeutics USD 40.0 million upfront and potentially more than USD 1.0 billion in milestone-based payments for the development of new ADCs.

Extensive research and rising funding for the development of novel antibody-drug conjugates by pharmaceutical companies is projected to drive market growth. For instance, in April 2021, Adcendo and Adcentrx, two new startups raised funding of around USD 112.0 million for the development of ADCs with their new approach to the treatment of cancer.

Adcendo raised USD 51.0 million for the development of new ADCs that target endocytic receptors, which play the role of the drug delivery body. Adcentrx raised USD 50.0 million for its ADC research programs.

Stringent reimbursement policies for ADCs may restrain the market growth due to the high cost associated with the treatment of ADCs as compared to the alternative conventional treatments such as monoclonal antibodies therapy & chemotherapy. This higher cost of treatment is expected to impede reimbursement coverage.

For instance, in February 2020, National Centre for Pharmaco economics, Ireland, gave a negative review for Roche’s Kadcyla (trastuzumab emtansine) for reimbursement consideration due to its low cost-effectiveness.

The rising geriatric population coupled with the increasing prevalence of the diseases such as multiple myeloma (MM) is expected to drive demand for ADCs, thereby driving the market growth during the forecast period. Multiple myeloma (MM) is a disease of the aging population, and nearly 30,000 new cases of MM were diagnosed in 2021.

The median age of diagnosed patients with multiple myeloma is 70 years. Thus, the introduction of new ADCs for the treatment of multiple myeloma is expected to boost market growth. For instance, in August 2020, the FDA approved BLENREP by GlaxoSmithKline as a monotherapy to treat relapsed or refractory multiple myeloma. Blenrep was the first anti-BCMA therapy approved for the treatment of multiple myeloma.

Antibody drug Conjugates Market Report Highlights

  • Breast cancer dominated the market in 2021, owing to the high prevalence of breast cancer and the availability of multiple ADC products for treating the breast cancer.
  • Cleavable linker segment dominated the market in 2021 due to the rising adoption of cleavable linker technology in commercial ADC products and the advantages associated with the use of cleavable linkers over other linker technology.
  • North America dominated the market in 2021 due to the presence of key pharmaceutical companies such as Pfizer, Inc, Gilead Life Sciences, Inc., and Seagen, Inc. and their strategic initiatives for the development of new ADCs.

Industry Outlooks

Driver Impact Analysis

  • Presence Of Strong Product Pipeline
  • Growing Geriatric Population Base
  • Increasing Incidence and Prevalence Of Cancer

Market Restraint Analysis

  • High Manufacturing Cost and Downstream Processing Challenges For ADCs
  • Stringent Reimbursement Policies For ADCs

Penetration and Growth Prospect Mapping

SWOT Analysis; by Factor (Political & Legal, Economic and Technological)

Porter’s Five Forces Analysis

Pipeline Analysis

Company Profiles

  • Takeda Pharmaceutical Company Limited
  • F. Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Astrazeneca
  • Gilead Sciences, Inc.
  • Astellas Pharma, Inc.
  • Seagen, Inc.
  • Daiichi Sankyo Company, Limited
  • GlaxoSmithKline plc
  • Adc Therapeutics Saa

For more information about this report visit


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900